Get started
Work

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

Year: 2022
Type: article
Source: Blood
DOI: 10.1182/blood-2022-158147
Authors: John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison
Institutions: Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Azienda Ospedaliero Universitaria Maggiore della Carita, University of Toronto, Istituto di Ematologia di Bologna, KU Leuven, Memorial Sloan Kettering Cancer Center, University of Michigan, U-M Rogel Cancer Center, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Moffitt Cancer Center, Université Paris Cité, Hôpital Saint-Louis, The University of Texas MD Anderson Cancer Center, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, Constellation Pharmaceuticals (United States), Guy's and St Thomas' NHS Foundation Trust
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: closed
OpenAlex ID: W4310099677
FWCI: 0.639
Cites:
Cited by: 5
Related to: 10